Consequently, several clinical trials have illustrated that MGMT promoter methylation is associated with improved survival compared to unmethylated tumors and is an independent prognostic factor in high-grade astrocytoma (102, 103). Here, MGMT is linked to astrocytoma (excluding glioblastoma).